8-K: Accelerate Diagnostics Reports Preliminary Q1 2024 Results, Highlights Progress on Wave System

Accelerate Diagnostics announced preliminary first quarter 2024 financial results, noting progress with their Accelerate Wave system and securing long-term customer contracts.

Summary

• Accelerate Diagnostics reported preliminary financial results for the first quarter of 2024, ending March 31.
• Net sales were $2.9 million, a slight increase from $2.8 million in the same quarter of the previous year.
• Consumable product revenues increased by 7% year-over-year.
• Gross margin decreased to approximately 25% from 36% in the prior year due to a lower mix of capital instrument sales.
• Selling, general, and administrative costs decreased significantly to $5.7 million from $10.1 million year-over-year, primarily due to lower employee-related expenses.
• Research and development costs also decreased to $5.2 million from $7.0 million year-over-year, due to lower employee and third-party development costs.
• The net loss for the quarter was $17.0 million, or $0.88 per share.
• Cash used in the first quarter was approximately $9.0 million, net of financing, including $1 million in pre-paid annual expenses.
• The company installed its first pre-clinical trial site for the Accelerate Wave system and is targeting the start of clinical trials towards the end of the second quarter.
• They are also developing their Gram Positive PBC menu and have secured long-term contracts with approximately 70% of their U.S. Pheno customer base.

Sentiment

Score: 4

Explanation: The document presents mixed results. While there is progress in product development and customer contracts, the significant net loss, decreased gross margin, and high cash burn rate raise concerns. The preliminary nature of the results also adds uncertainty.

Positives

• The company successfully installed its first pre-clinical trial site for the Accelerate Wave system, demonstrating progress in its development.
• The company has secured long-term contracts with a significant portion (70%) of its U.S. Pheno customer base, providing revenue stability.
• Consumable product revenues increased by 7% year-over-year, indicating growth in recurring revenue streams.
• Selling, general, and administrative costs decreased significantly, showing improved cost management.
• Research and development costs decreased, reflecting a more efficient use of resources.
• The company added 12 new contracted Pheno instruments in the U.S., expanding its installed base.

Negatives

• Gross margin decreased to approximately 25% from 36% in the prior year, primarily due to a lower mix of capital instrument sales.
• The company reported a net loss of $17.0 million for the quarter, or $0.88 per share.
• Cash used in the first quarter was approximately $9.0 million, indicating a significant cash burn rate.
• The preliminary results are subject to revisions based on closing procedures and external auditor review, creating uncertainty.

Risks

• The company's financial results are preliminary and subject to change, which could impact investor confidence.
• The company is experiencing a decline in gross margin due to a shift in sales mix, which could affect profitability.
• The company is incurring significant net losses and cash burn, raising concerns about its financial sustainability.
• The company's ability to obtain additional capital to meet its financial obligations is uncertain.
• The company faces risks related to regulatory approvals for its products.
• The company is subject to volatility in the global economy, which could impact its suppliers and customers.

Future Outlook

The company is targeting the start of clinical trials for the Accelerate Wave system towards the end of the second quarter and continues to develop its Gram Positive PBC menu. They also expect to file full financial results for the quarter ended March 31, 2024 on Form 10-Q.

Management Comments

• During the quarter we installed our first pre-clinical trial site demonstrating our ability to successfully ship, install, train and run the Accelerate WaveTM system with Gram-Negative Positive Blood Culture samples in a clinical microbiology lab, commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc.
• We continue to target starting our clinical trial towards the end of the second quarter.
• The interest in Wave remains very high due to its differentiated and highly valued features, Mr. Phillips continued.

Industry Context

The announcement highlights Accelerate Diagnostics' focus on addressing antibiotic resistance and sepsis, which are significant global health challenges. The development of the Accelerate Wave system and its rapid susceptibility testing capabilities align with the industry's push for faster and more effective diagnostic solutions. The company's efforts to secure long-term contracts also reflect a trend towards recurring revenue models in the diagnostics sector.

Comparison to Industry Standards

• Accelerate Diagnostics' focus on rapid antibiotic susceptibility testing aligns with the broader industry trend towards faster diagnostics, similar to companies like BioMérieux and Cepheid, which also offer rapid testing solutions.
• The company's gross margin of 25% is lower than some established diagnostics companies, which often have gross margins above 50%, indicating potential challenges in cost management or pricing strategy.
• The significant reduction in SG&A and R&D expenses is a positive sign, but the company's net loss of $17 million is substantial compared to more profitable peers, suggesting a need for further operational improvements.
• The company's cash burn of $9 million in the quarter is a concern, as many diagnostics companies aim for positive cash flow or at least a lower burn rate, especially at this stage of development.

Stakeholder Impact

• Shareholders may be concerned about the significant net loss and cash burn.
• Employees may be affected by the cost-cutting measures, particularly in employee-related expenses.
• Customers may benefit from the new Accelerate Wave system and the long-term contracts.
• Suppliers may be impacted by the company's financial performance and cost-cutting measures.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company plans to start clinical trials for the Accelerate Wave system towards the end of the second quarter.
• The company will continue development of its Gram Positive PBC menu.
• The company will file full financial results for the quarter ended March 31, 2024 on Form 10-Q.
• Management will host a conference call to review the first quarter 2024 results.

Key Dates

Keywords

Accelerate Diagnostics, Accelerate Wave, Pheno system, Gram-Negative, Gram-Positive, Blood Culture, Antibiotic Resistance, Sepsis, In Vitro Diagnostics, Financial Results, Clinical Trial, Revenue, Gross Margin, R&D, SG&A